Drug Profile
Research programme: amino-acyl-tRNA-synthetase-inhibitors - Allied-Bristol Life Sciences
Latest Information Update: 23 Aug 2023
Price :
$50
*
At a glance
- Originator Harvard University
- Developer Allied-Bristol Life Sciences; Harvard University
- Class
- Mechanism of Action Amino acyl tRNA synthetase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Autoimmune disorders; Fibrosis
Most Recent Events
- 23 Aug 2023 Discontinued - Preclinical for Autoimmune disorders in USA (unspecified route)
- 23 Aug 2023 Discontinued - Preclinical for Fibrosis in USA (unspecified route)
- 28 Jul 2019 No recent reports of development identified for preclinical development in Autoimmune-disorders in USA